Latest Conference Articles

At the 25th European Academy of Dermatology and Venereology Congress in Vienna, Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health, discussed hurdles to proper drug adherence in HIV treatment.

Clinical trial presented at the 25th Annual European Academy of Dermatology and Venereology Congress found a new topical allantoin cream can help treat epidermolysis bullosa.

Stephen I. Katz, MD, PhD, director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, kicked off the European Academy of Dermatology and Venereology Congress highlighting the future of dermatology treatment.

Data presented at the European Academy of Dermatology and Venereology (EADV) Annual Congress shows safety and efficacy of apremilast (Otezla) over three years.

Aleksandar L. Krunic, MD, PhD, discusses tumor removal in Mohs disease during the 25th European Academy of Dermatology and Venereology Congress.

Aleksandar L. Krunic, MD, PhD, discusses treatment strategies for rare tumor types in Mohs disease during the 25th European Academy of Dermatology and Venereology Congress.

Although it's difficult to determine exactly how many patients experience opioid-induced constipation, the large quantities of prescribed opioids in circulation create widespread potential for this bothersome adverse effect.

The opioid overdose death toll has been steadily increasing for more than a decade, making it a leading cause of accidental death in the United States.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how pharmacists can help prevent OIC.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses counseling points for OIC patients.

Jeffrey Gudin, MD, outlines the steps pharmacists should take to reduce opioid-induced constipation.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses the latest advancements in OIC treatment.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses potential adverse effects associated with naloxone.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how pharmacy-based OIC care differs from other settings.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses how health-system pharmacists can assess patients' risk for opioid overdose.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses OTC recommendations for OIC symptoms.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how often pharmacists work with OIC patients.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses what pharmacists should tell patients about administering naloxone.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses key stakeholders involved in developing and implementing outpatient naloxone policies.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses how health-system and community pharmacists can work together to provide naloxone.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses prices of naloxone products.

Jeffrey Gudin, MD, describes the impact of opioid-induced constipation on patients taking opioids.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses where fiber supplementation fits into OIC care.

There are many misconceptions surrounding pain management, especially when it comes to opioids with abuse-deterrent properties.

J. David Haddox, DDS, MD, describes how clinicians can determine whether an opioid has abuse-deterrent properties.

J. David Haddox, DDS, MD, describes the pharmacist's role in deterring opioid abuse.

The answer may surprise you.

J. David Haddox, DDS, MD, describes the most common method of opioid abuse.

J. David Haddox, DDS, MD, corrects a misconception about opioids with abuse-deterrent properties.

J. David Haddox, DDS, MD, explains how most nonmedical opioid users obtain the drug.